Address: 11560 Room A, 14F., No.3, Yuancyu St., Nangang District, Taipei City 11560, Taiwan
Tel: +886 2 2653-5200
Web: http://www.medigen.com.tw/index.php
Medigen, Inc. is a biotechnology company that specializes in biomedical research and consulting services in the areas of infectious diseases, cancer, and human gene therapy. Our expertise are prostate cancer vaccines and vaccines against emerging and biodefense diseases. We also provide our clients with expert consulting services and contract research in these fields, including experiment design, intellectual property development, and publishing and communicating data to the scientific community and government agencies.
Medigen Biotechnology Corp. was founded in Taiwan in 1999, focusing on the development of biopharmaceuticals for liver diseases and cancers. MBC intends to further extending global partnership in new drug development and nucleic acid tests, particularly in the field of oncology and liver diseases. MBC has a paid-in capital of NT$710,000,000 (approximately US$21.5M), and is listed on Emerging market of Taiwan.
The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative…
Medigen was created in 1999 and is a listed company. How did the vision for the company come about, and what was it that attracted today’s main shareholders to Medigen?…
Lee Po-Chang, director general of Taiwan’s National Health Insurance Administration (NHIA) details his main priorities to further strengthen the country’s widely acclaimed single-payer health system, which already stands as one…
In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug…
Wu Tsung-Tsong, Minister Without Portfolio of the Republic of China (Taiwan) supervises and coordinates Taiwan’s Biomedical Industry Innovation Program. In this exclusive interview, he documents his main priorities and the…
Leveraging Taiwan’s remarkable talent pool in chemistry, some of the country’s fastest-growing companies have been concentrating their efforts on technology platforms that allow them to develop a plethora of potentially…
Johnsee Lee, a leading figure in the Taiwanese biotech and pharmaceutical sectors and Chairman of Taiwan Bio Industry Organization, the largest and one of the most influential biotechnology associations in…
Founded in 2012, Senhwa Biosciences is mainly engaged in the development and clinical study of small molecule drugs to treat various types of cancer, and its drug development pipelines include…
Wayne Wang, director general of Hsinchu Science Park (HSP), the country’s largest and oldest innovation cluster and the first in Taiwan to establish a science park exclusively dedicated to the…
Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s…
Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s…
Wang Yu Pei, general manager of Nang Kuang Pharmaceutical, Taiwan’s indisputable market leader for injectable products, provides insights into the global ambitions of the company as Nang Kuang is about…
With more than 100 peer-reviewed articles published and more than ten thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the department of Psychiatry and Behavioral…
Ko-Chung Lin, founder and CEO of PharmaEssentia, documents the main specificities of the company’s groundbreaking ropeginterferon alfa-2b, a once-every-two-week interferon displaying a unique toxicity profile. In this regard, Mr. Lin…
See our Cookie Privacy Policy Here
